Biocytogen provides integrated solutions for next-generation antibody drug development to the global biomedical communities. Powered by cutting-edge gene editing technologies and a state-of-the-art animal facility, Biocytogen developed a seamlessly integrated platform for efficient antibody drug discovery and validation, including animal model generation, therapeutic antibody discovery (via RenMab™ Mouse), and in vivo/in vitro preclinical validation studies. With facilities in the US and China, our CRO division provides models and preclinical services to clients around the globe. In addition, we have a scientific team working on in-house research and discovery of novel antibody therapeutics for licensing and co-development partnerships. To learn more about our asset licensing division, clinical subsidiary, and executive leadership, visit the links below: